NDA 215559 · Ipsen
Sohonos
Palovarotene · Oral · Retinoid
NovelPriority reviewOrphanCDER novel approval, Aug 16, 2023: To reduce the volume of new heterotopic ossification in adults and pediatric patients (aged 8 years and older for females and 10 years and older for males) with fibrodysplasia ossificans progressiva
Last checked: Nov 20, 2026Latest source record: Sep 18, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2023
Aug 16, 2023
Approved uses
2
Original approval plus efficacy supplements
Registered trials
10
2 Phase 3, 0 recruiting
FAERS reports
71
38 serious, 2 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: EMBRYO-FETAL TOXICITY and PREMATURE EPIPHYSEAL CLOSURE IN GROWING PEDIATRIC PATIENTS WARNING: EMBRYO-FETAL TOXICITY and PREMATURE EPIPHYSEAL CLOSURE IN GROWING PEDIATRIC PATIENTS See full prescribing information for complete boxed warning. SOHONOS is contraindicated in pregnancy ( 5.1 , 8.1 ) Because of the risk of teratogenicity and to minimize fetal exposure, SOHONOS is to be administered only if conditions for pregnancy prevention are met ( 5.1 , 8.1 ) SOHONOS causes premature epiphyseal closure in growing pediatric patients with FOP, close monitoring is recommended ( 5.2 , 8.4 ) Embryo-Fetal Toxicity SOHONOS is contraindicated in pregnancy. SOHONOS may cause fetal harm. Because of the risk of teratogenicity and to minimize fetal exposure, SOHONOS is to be administered only if conditions for pregnancy prevention are met [see Warnings and Precautions (5.1) and Use in Specific...
What it is approved for
From the label in effect Sep 24, 2026.
SOHONOS is indicated for the reduction in volume of new heterotopic ossification in adults and pediatric patients aged 8 years and older for females and 10 years and older for males with fibrodysplasia ossificans progressiva (FOP). SOHONOS is a retinoid indicated for reduction in the volume of new heterotopic ossification in adults and children aged 8 years and older for females and 10 years and older for males with fibrodysplasia ossificans progressiva (FOP) ( 1 ).
Mechanism: In patients with FOP, abnormal bone formation, including heterotopic ossification (HO), is driven by a gain-of-function mutation in the bone morphogenetic protein (BMP) type I receptor ALK2 (ACVR1). Palovarotene is an orally bioavailable retinoic acid receptor agonist, with particular selectivity at the gamma subtype of RAR. Through binding to RARγ, palovarotene decreases the BMP/ALK2 downstream signaling pathway by inhibiting the phosphorylation of SMAD1/5/8, which reduces ALK2/SMAD-dependent chondrogenesis and osteocyte differentiation resulting in reduced endochondral bone formation.
Therapeutic areas: Ophthalmology
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Mar 13, 2025 Supplement 2 · Efficacy OrphanLabelMedication GuideLetter
- Aug 16, 2023 Original approval · Type 1 - New Molecular Entity · priority review NovelOrphanLabelLetterReview
5 products under this application
- SOHONOS · PALOVAROTENE 10MG · CAPSULE, ORAL · Prescription
- SOHONOS · PALOVAROTENE 2.5MG · CAPSULE, ORAL · Discontinued
- SOHONOS · PALOVAROTENE 1MG · CAPSULE, ORAL · Prescription
- SOHONOS · PALOVAROTENE 5MG · CAPSULE, ORAL · Prescription
- SOHONOS · PALOVAROTENE 1.5MG · CAPSULE, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Palovarotene" as an intervention, any sponsor and status, largest first.
- An Efficacy and Safety Study of Palovarotene for the Treatment of MOPivotal-lookingTerminated
Clementia Pharmaceuticals Inc.Industry
NCT03442985 · 193 participants · Start Mar 22, 2018 · Primary completion Mar 24, 2020
Drug: Palovarotene 2.5 mg; Palovarotene 5.0 mg · For: Exostoses, Multiple Hereditary
Sites: Los Angeles, California; Sacramento, California; San Francisco, California · 31 sites in all
- An Efficacy and Safety Study of Palovarotene for the Treatment of Fibrodysplasia Ossificans Progressiva.Pivotal-lookingCompleted
Clementia Pharmaceuticals Inc.Industry
NCT03312634 · 107 participants · Start Nov 30, 2017 · Primary completion Jan 24, 2020
Drug: Palovarotene · For: Fibrodysplasia Ossificans Progressiva
Sites: San Francisco, California; Rochester, Minnesota; Philadelphia, Pennsylvania · 16 sites in all
IpsenIndustry
NCT05027802 · 61 participants · Start Mar 14, 2022 · Primary completion Nov 30, 2024
Drug: Palovarotene · For: Fibrodysplasia Ossificans Progressiva (FOP)
Sites: San Francisco, California; Rochester, Minnesota; Philadelphia, Pennsylvania · 13 sites in all
Clementia Pharmaceuticals Inc.Industry
NCT02279095 · 58 participants · Start Oct 9, 2014 · Primary completion Sep 20, 2022
Drug: Palovarotene dose level 1; Palovarotene dose level 2 and 2 more · For: Fibrodysplasia Ossificans Progressiva
Sites: San Francisco, California; Rochester, Minnesota; Philadelphia, Pennsylvania · 8 sites in all
Clementia Pharmaceuticals Inc.Industry
NCT04762355 · 48 participants · Start Aug 30, 2018 · Primary completion Jan 3, 2019
Drug: Palovarotene; Vehicle · For: Dry Eye Disease
Sites: Québec, Canada
Clementia Pharmaceuticals Inc.Industry
NCT04829773 · 48 participants · Start Jan 3, 2019 · Primary completion Mar 29, 2019
Drug: Palovarotene; midazolam · For: Fibrodysplasia Ossificans Progressiva
Sites: Cambridge, Massachusetts
Clementia Pharmaceuticals Inc.Industry
NCT02190747 · 40 participants · Start Jul 14, 2014 · Primary completion May 23, 2016
Drug: Palovarotene; Placebo · For: Fibrodysplasia Ossificans Progressiva
Sites: San Francisco, California; Philadelphia, Pennsylvania; Paris, France · 4 sites in all
IpsenIndustry
NCT06908954 · 31 participants · Start Mar 14, 2025 · Primary completion Feb 6, 2026
Drug: Palovarotene; Palovarotene and 1 more · For: Hepatic Impairment; Healthy
Sites: Miami, Florida; Orlando, Florida; San Antonio, Texas · 4 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- condition aggravated33
- off label use17
- dry skin14
- product dose omission issue14
- fibrodysplasia ossificans progressiva10
- pruritus10
- skin exfoliation10
- alopecia6
- rash6
- drug ineffective5
- cross sensitivity reaction4
- dyspepsia3
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2022 | 3 |
| 2023 | 3 |
| 2024 | 17 |
| 2025 | 22 |
| 2026 | 26 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
To Be Discontinued · updated Aug 31, 2026
SOHONOS, Capsule, 2.5 mg (NDC 15054-0025-1). Discontinuation of the manufacture of the drug
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Sohonos (Palovarotene)
2024 spending
$3.3M
Beneficiaries
n/a
31 claims
Per beneficiary
n/a
$2,308.72 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $0 |
| 2023 | $0 |
| 2024 | $3,287,447 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- A Pharmacokinetic, Safety, and Tolerability Trial of Palovarotene in Healthy Japanese and Non-Japanese Participants.
Dube L, Haga N, Grogan D, et al. · Eur J Drug Metab Pharmacokinet 2023 · Randomized Controlled Trial, Clinical Trial, Phase I
- Palovarotene for patients with multiple hereditary exostosis: results of MO-Ped, a terminated, randomized, placebo-controlled, double-blind phase 2 trial.
Sangiorgi L, Conrad EU, Shih F, et al. · Sci Rep 2025 · Clinical Trial, Phase II, Randomized Controlled Trial
- Palovarotene for Fibrodysplasia Ossificans Progressiva (FOP): Results of a Randomized, Placebo-Controlled, Double-Blind Phase 2 Trial.
Pignolo RJ, Baujat G, Hsiao EC, et al. · J Bone Miner Res 2022 · Randomized Controlled Trial, Clinical Trial, Phase II
- The Pharmacokinetic Profile of Palovarotene: An Open-Label Phase I Trial Investigating the Effect of Food and Potential for Drug-Drug Interaction in Healthy Participants.
Marino R, Dube L, Ogier J, et al. · Eur J Drug Metab Pharmacokinet 2023 · Clinical Trial, Phase I
- Palovarotene impact on fibrodysplasia ossificans progressiva (FOP): data from month 48 of the phase III MOVE trial.
Pignolo RJ, Hsiao EC, Al Mukaddam M, et al. · JBMR Plus 2026 · Clinical Trial
- A Randomised Phase I Study to Assess the Safety, Tolerability and Pharmacokinetics of Palovarotene Ophthalmic Solution.
Foster WJ, Strahs AL, Small KW, et al. · Drugs R D 2023 · Randomized Controlled Trial, Clinical Trial, Phase I
Sponsor: Ipsen
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.